← Back to headlines
Climb Bio Receives FDA Fast Track Designation and BTIG Buy Rating
Climb Bio (CLYM) has been granted FDA Fast Track designation, and BTIG has issued a "Buy" rating for the small-cap stock. This news has sparked discussions about the company's investment potential.
20 Apr, 14:48 — 20 Apr, 14:48
Sources
Showing 1 of 1 sources
Related Stories
Lionel Richie Hospitalized in ICU Following St. Louis Concert
52m ago
Anna Hazare admitted to Mumbai hospital's ICU with acute dehydration, kidney issue
5h ago
Ebola Outbreak in Democratic Republic of Congo Surpasses 6,000 Cases
8h ago
England Pharmacies to Offer Free Quick Cholesterol Screening Tests
16h ago